Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study.
<h4<Background and aims</h4<Fibrosis progression is the most important prognostic factor, and insulin resistance is one of the main mechanisms associated with fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD). We evaluate the association between baseline insulin resistance and future fibrosis progression in patients with NAFLD without diabetes.<h4<Approach and results</h4<This retrospective longitudinal study with 8-year follow-up period included 32,606 (men, 83%) participants aged <20 years (average age, 38.0 years) without diabetes at baseline who completed at least two comprehensive health checkups from January 1, 2010 to December 31, 2018. NAFLD was diagnosed based on ultrasonography. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate baseline insulin resistance. Fibrosis progression was assessed using the aspartate aminotransferase to platelet ratio index (APRI). The advanced liver fibrosis with an APRI value above the intermediate fibrosis probability (≥0.5) developed in a total of 2,897 participants during 136,108 person-years. 114 participants progressed to a high fibrosis probability stage (APRI <1.5) during 141,064 person-years. Using the lowest baseline HOMA-IR quartile group (Q1) as a reference, the multivariate-adjusted hazard ratio (HR) for development of advanced liver fibrosis (APRI ≥0.5) in the highest baseline HOMA-IR quartile group (Q4) was 1.95 (95% confidence interval [CI] 1.74-2.19; Model 4). And the HR for development of advanced liver fibrosis with high fibrosis probability was 1.95 (95% CI 1.10-3.46; Model 4). The positive association was maintained throughout the entire follow-up period. The baseline HOMA-IR model was superior to the baseline body mass index (BMI) model in predicting the progression of fibrosis probability.<h4<Conclusions</h4<In this longitudinal study, we found that the degree of baseline insulin resistance, assessed by HOMA-IR values, was positively associated with future fibrosis progression in patients with NAFLD without diabetes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
PLoS ONE - 16(2021), 8, p e0255535 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dae-Jeong Koo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1371/journal.pone.0255535 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ052849031 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ052849031 | ||
| 003 | DE-627 | ||
| 005 | 20230503064855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0255535 |2 doi | |
| 035 | |a (DE-627)DOAJ052849031 | ||
| 035 | |a (DE-599)DOAJ5d948581265642858028512c8c320190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Dae-Jeong Koo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <h4<Background and aims</h4<Fibrosis progression is the most important prognostic factor, and insulin resistance is one of the main mechanisms associated with fibrosis progression in patients with nonalcoholic fatty liver disease (NAFLD). We evaluate the association between baseline insulin resistance and future fibrosis progression in patients with NAFLD without diabetes.<h4<Approach and results</h4<This retrospective longitudinal study with 8-year follow-up period included 32,606 (men, 83%) participants aged <20 years (average age, 38.0 years) without diabetes at baseline who completed at least two comprehensive health checkups from January 1, 2010 to December 31, 2018. NAFLD was diagnosed based on ultrasonography. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate baseline insulin resistance. Fibrosis progression was assessed using the aspartate aminotransferase to platelet ratio index (APRI). The advanced liver fibrosis with an APRI value above the intermediate fibrosis probability (≥0.5) developed in a total of 2,897 participants during 136,108 person-years. 114 participants progressed to a high fibrosis probability stage (APRI <1.5) during 141,064 person-years. Using the lowest baseline HOMA-IR quartile group (Q1) as a reference, the multivariate-adjusted hazard ratio (HR) for development of advanced liver fibrosis (APRI ≥0.5) in the highest baseline HOMA-IR quartile group (Q4) was 1.95 (95% confidence interval [CI] 1.74-2.19; Model 4). And the HR for development of advanced liver fibrosis with high fibrosis probability was 1.95 (95% CI 1.10-3.46; Model 4). The positive association was maintained throughout the entire follow-up period. The baseline HOMA-IR model was superior to the baseline body mass index (BMI) model in predicting the progression of fibrosis probability.<h4<Conclusions</h4<In this longitudinal study, we found that the degree of baseline insulin resistance, assessed by HOMA-IR values, was positively associated with future fibrosis progression in patients with NAFLD without diabetes. | ||
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Mi Yeon Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Inha Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Sun Joon Moon |e verfasserin |4 aut | |
| 700 | 0 | |a Hyemi Kwon |e verfasserin |4 aut | |
| 700 | 0 | |a Se Eun Park |e verfasserin |4 aut | |
| 700 | 0 | |a Eun-Jung Rhee |e verfasserin |4 aut | |
| 700 | 0 | |a Won-Young Lee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t PLoS ONE |d Public Library of Science (PLoS), 2007 |g 16(2021), 8, p e0255535 |w (DE-627)DOAJ000113018 |x 19326203 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:8, p e0255535 |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0255535 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5d948581265642858028512c8c320190 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0255535 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1932-6203 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 8, p e0255535 | ||